drugset / Trial / NCT04286711

Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer

NCT04286711

Phase 1/2 Unknown 52 enrolled China Medical University, China
NaSingle-groupOpen-labelTreatment

Summary

This study is to evaluate the tolerance of albumin paclitaxel combined with apatinib and Camrelizumab in the second-line treatment of advanced gastric cancer to determine the maximum tolerable dose (MTD) of the combination.

Timeline

Start
2020-03
Primary completion
2020-08
Completion
2021-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 200 mg Intravenous
Subject Paclitaxel Small molecule 75 mg/m2 Intravenous
Subject Paclitaxel Small molecule 100 mg/m2 Intravenous
Subject Paclitaxel Small molecule 125 mg/m2 Intravenous
Subject Rivoceranib Small molecule 250 mg Oral

Indications